

Using marijuana during pregnancy could cause birth defects or other health issues to your unborn child.

Batch Number:	K101023CLEO
Harvest Date:	07/02/2023
Manufacture Date:	11/16/2023
Extraction Method:	N/A Collected from Trimming Process
Distribution Chain:	Globe Farmacy Inc (00000045DCYU00647140) to Globe Farmacy Inc (00000108ESND56774062)



Kief: Cleo

Sample ID: 2310APO2713.12622 Strain: Cleo

LABS

Matrix: Concentrates & Extracts Type: Kief Produced:

Collected: 10/11/2023 04:23 pm Received: 10/11/2023

Completed: 10/16/2023 Batch #: K101023CLEO Client

Globe Farmacy Inc Lic. # 00000045DCYU00647140

Lot #:



Summary		
Test	Date Tested	Result
Batch		Pass
Cannabinoids	10/13/2023	Complete
Residual Solvents	10/12/2023	Pass
Microbials	10/16/2023	Pass
Mycotoxins	10/12/2023	Pass
Pesticides	10/12/2023	Pass
Heavy Metals	10/13/2023	Pass

Cannabinoids Complete

58.0255% Total THC	0.10 8 Total 0		68.80229 Total Cannabi	NT Total Terpenes
Analyte LOD	LOQ	Result	Result	Q
%	%	%	mg/g	
THCa	0.1000	60.0607	600.607	
Δ9-THC	0.1000	5.3523	53.523	
Δ8-THC	0.1000	ND	ND	
THCV	0.1000	ND	ND	
CBDa	0.1000	0.1240	1.240	
CBD	0.1000	ND	ND	
CBDVa	0.1000	ND	ND	
CBDV	0.1000	ND	ND	
CBN	0.1000	ND	ND	
CBGa	0.1000	2.6693	26.693	
CBG	0.1000	0.4737	4.737	
CBC	0.1000	0.1222	1.222	
Total THC		58.0255	580.2550	
Total CBD		0.1088	1.0880	
Total		68.8022	688.022	

Date Tested: $10/13/2023\,07:00\,\text{am}$





Bryant Kearl Lab Director 10/16/2023



(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

2 of 6

Kief: Cleo

Sample ID: 2310APO2713.12622 Strain: Cleo

Matrix: Concentrates & Extracts Type: Kief

Produced:

Collected: 10/11/2023 04:23 pm

Received: 10/11/2023 Completed: 10/16/2023 Batch #: K101023CLEO

Client

Globe Farmacy Inc Lic. # 00000045DCYU00647140

Lot #:

Pesticides Pass

Analyte	LOQ	Limit	Mass	Q	Status	Analyte	LOQ	Limit	Mass	Q	Status
	PPM	PPM	PPM				PPM	PPM	PPM		
Abamectin	0.2500	0.5000	ND		Pass	Hexythiazox	0.5000	1.0000	ND		Pass
Acephate	0.2000	0.4000	ND		Pass	lmazalil	0.1000	0.2000	ND		Pass
Acetamiprid	0.1000	0.2000	ND		Pass	Imidacloprid	0.2000	0.4000	ND	M1	Pass
Aldicarb	0.2000	0.4000	ND		Pass	Kresoxim Methyl	0.2000	0.4000	ND		Pass
Azoxystrobin	0.1000	0.2000	ND		Pass	Malathion	0.1000	0.2000	ND		Pass
Bifenazate	0.1000	0.2000	ND	M1	Pass	Metalaxyl	0.1000	0.2000	ND		Pass
Bifenthrin	0.1000	0.2000	ND	M2	Pass	Methiocarb	0.1000	0.2000	ND		Pass
Boscalid	0.2000	0.4000	ND		Pass	Methomyl	0.2000	0.4000	ND		Pass
Carbaryl	0.1000	0.2000	ND		Pass	Myclobutanil	0.1000	0.2000	ND		Pass
Carbofuran	0.1000	0.2000	ND		Pass	Naled	0.2500	0.5000	ND		Pass
Chlorantraniliprole	0.1000	0.2000	ND	M1	Pass	Oxamyl	0.5000	1.0000	ND		Pass
Chlorfenapyr	0.5000	1.0000	ND		Pass	Paclobutrazol	0.2000	0.4000	ND		Pass
Chlorpyrifos	0.1000	0.2000	ND	M2	Pass	Permethrins	0.1000	0.2000	ND	M2	Pass
Clofentezine	0.1000	0.2000	ND		Pass	Phosmet	0.1000	0.2000	ND		Pass
Cyfluthrin	0.5000	1.0000	ND	M1	Pass	Piperonyl	1.0000	2.0000	ND		Pass
Cypermethrin	0.5000	1.0000	ND		Pass	Butoxide					
Daminozide	0.5000	1.0000	ND		Pass	Prallethrin	0.1000	0.2000	ND		Pass
Diazinon	0.1000	0.2000	ND		Pass	Propiconazole	0.2000	0.4000	ND		Pass
Dichlorvos	0.0500	0.1000	ND		Pass	Propoxur	0.1000	0.2000	ND		Pass
Dimethoate	0.1000	0.2000	ND		Pass	Pyrethrins	0.5000	1.0000	ND		Pass
Ethoprophos	0.1000	0.2000	ND		Pass	Pyridaben	0.1000	0.2000	ND		Pass
Etofenprox	0.2000	0.4000	ND	M2	Pass	Spinosad	0.1000	0.2000	ND	M1	Pass
Etoxazole	0.1000	0.2000	ND		Pass	Spiromesifen	0.1000	0.2000	ND		Pass
Fenoxycarb	0.1000	0.2000	ND		Pass	Spirotetramat	0.1000	0.2000	ND	M1	Pass
Fenpyroximate	0.2000	0.4000	ND		Pass	Spiroxamine	0.2000	0.4000	ND	M1	Pass
Fipronil	0.2000	0.4000	ND	M1	Pass	Tebuconazole	0.2000	0.4000	ND		Pass
Flonicamid	0.5000	1.0000	ND		Pass	Thiacloprid	0.1000	0.2000	ND		Pass
Fludioxonil	0.2000	0.4000	ND		Pass	Thiamethoxam	0.1000	0.2000	ND	M1	Pass
						Trifloxystrobin	0.1000	0.2000	ND	M2	Pass

Date Tested: 10/12/2023 07:00 am





Bryant Kearl Lab Director 10/16/2023



(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

3 of 6

Kief: Cleo

Sample ID: 2310APO2713.12622

Strain: Cleo

Matrix: Concentrates & Extracts Type: Kief

Produced:

Collected: 10/11/2023 04:23 pm Received: 10/11/2023

Completed: 10/16/2023

Batch #: K101023CLEO

Client

Globe Farmacy Inc Lic. # 00000045DCYU00647140

Lot #:

Microbials **Pass**

Analyte	Limit	Result	Status	Q
Salmonella SPP	Detected/Not Detected in 1g	ND	Pass	
Aspergillus Flavus Aspergillus Fumigatus or Aspergillus Niger	Detected/Not Detected in 1g	ND	Pass	
Aspergillus terreus	Detected/Not Detected in 1g	ND	Pass	

Analyte	LOQ	Limit	Result	Status	Q
	CFU/g	CFU/g	CFU/g		
E. Coli	10.0	100.0	< 10 CFU/g	Pass	

Date Tested: 10/16/2023 12:00 am

Pass Mycotoxins

Analyte	LOD	LOQ	Limit	Units	Status	Q
	μg/kg	µg/kg	μg/kg	μg/kg		
B1	5	10	20	ND	Pass	
B2	5	10	20	ND	Pass	
G1	5	10	20	ND	Pass	
G2	5	10	20	ND	Pass	M1
Total Aflatoxins	5	10	20	ND	Pass	M1
Ochratoxin A	5	10	20	ND	Pass	

Date Tested: 10/12/2023 07:00 am

Heavy Metals Pass

Analyte	LOD	LOQ	Limit	Units	Status	Q
	PPM	PPM	PPM	PPM		
Arsenic	0.0660	0.1330	0.4000	ND	Pass	
Cadmium	0.0660	0.1330	0.4000	ND	Pass	
Lead	0.1660	0.3330	1.0000	ND	Pass	
Mercury	0.0330	0.0660	0.2000	ND	Pass	

Date Tested: 10/13/2023 12:00 am





Bryant Kearl Lab Director 10/16/2023







(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

4 of 6

Kief: Cleo

Sample ID: 2310APO2713.12622

Strain: Cleo

Matrix: Concentrates & Extracts
Type: Kief

Produced:

Collected: 10/11/2023 04:23 pm

Received: 10/11/2023 Completed: 10/16/2023 Batch #: K101023CLEO Client

Globe Farmacy Inc Lic. # 00000045DCYU00647140

Lot #:

Residual Solvents

Analyte	LOQ	Limit	Mass	Status	Q
	PPM	PPM	PPM		Pass
Acetone	381.0000	1000.0000	ND	Pass	
Acetonitrile	154.0000	410.0000	ND	Pass	
Benzene	1.0000	2.0000	ND	Pass	
Butanes	1914.0000	5000.0000	ND	Pass	
Chloroform	24.0000	60.0000	ND	Pass	
Dichloromethane	231.0000	600.0000	ND	Pass	
Ethanol	1910.0000	5000.0000	ND	Pass	
Ethyl-Acetate	1907.0000	5000.0000	ND	Pass	
Ethyl-Ether	1901.0000	5000.0000	ND	Pass	
n-Heptane	1892.0000	5000.0000	ND	Pass	
Hexanes	115.0000	290.0000	ND	Pass	
Isopropanol	1915.0000	5000.0000	ND	Pass	
Isopropyl-Acetate	1908.0000	5000.0000	ND	Pass	
Methanol	1141.0000	3000.0000	ND	Pass	
Pentane	1923.0000	5000.0000	ND	Pass	
Toluene	343.0000	890.0000	ND	Pass	
Xylenes + Ethyl Benzene	841.0000	2170.0000	ND	Pass	

LABS

Date Tested: 10/12/2023 07:00 am





Bryant Kearl Lab Director 10/16/2023







(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

5 of 6

Kief: Cleo

Sample ID: 2310APO2713.12622 Strain: Cleo

Matrix: Concentrates & Extracts Type: Kief Produced: Collected: 10/11/2023 04:23 pm Received: 10/11/2023 Completed: 10/16/2023 Batch #: K101023CLEO Client

Globe Farmacy Inc Lic. # 00000045DCYU00647140

Lot #:

Terpenes

Analyte LOQ Mass Mass Q Analyte LOQ Mass Mass Q



Primary Aromas



Date Tested:





Bryant Kearl Lab Director 10/16/2023



(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

6 of 6

Kief: Cleo

Sample ID: 2310APO2713.12622 Strain: Cleo

Matrix: Concentrates & Extracts
Type: Kief

Produced: Collected: 10/11/2023 04:23 pm Received: 10/11/2023 Completed: 10/16/2023 Batch #: K101023CLEO Client
Globe Farmacy Inc
Lic. # 00000045DCYU00647140

Lot #:

Qualifiers Definitions

Qualifier Notation	Qualifier Description
I1	The relative intensity of a characteristic ion in a sample analyte exceeded the acceptance criteria in subsection (L)(1) with respect to the reference spectra, indicating interference
L1	When testing for pesticides, fungicides, herbicides, growth regulators, heavy metals, or residual solvents, the percent recovery of a laboratory control sample is greater than the acceptance limits in subsection $(K)(2)(c)$, but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
M1	The recovery from the matrix spike in subsection (K)(4) was: a. High, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M2	The recovery from the matrix spike in subsection (K)(4) was: b. Low, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
М3	The recovery from the matrix spike in subsection (K)(4) was: c. Unusable because the analyte concentration was disproportionate to the spike level, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
R1	The relative percent difference for the laboratory control sample and duplicate exceeded the limit in subsection $(K)(3)$, but the recovery in subsection $(K)(2)$ was within acceptance criteria
V1	The recovery from continuing calibration verification standards exceeded the acceptance limits in subsection (J) (1)(b), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
Q2	The sample is heterogeneous, and sample homogeneity could not be readily achieved using routine laboratory practices – Used to denote that the sample as-received could not be fully pre-homogenized in packaging prior to microbiology analysis
Q3	Testing result is for informational purposes only and cannot be used to satisfy dispensary testing requirements in R9-17-317.01(A) or labeling requirements in R9-17-317





Confident Cannabis All Rights Reserved support@confidentcannabis.com (866) 506-5866 www.confidentcannabis.com



10/16/2023